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Abstract
Sensory neurons play an essential role in almost all painBackground: 
conditions, and have recently been classified into distinct subsets on the basis
of their transcriptomes. Here we have analysed alterations in dorsal root
ganglia (DRG) gene expression using microarrays in mouse models related to
human chronic pain.
Six different pain models were studied in male C57BL/6J mice: (1)Methods: 
bone cancer pain using cancer cell injection in the intramedullary space of the
femur; (2) neuropathic pain using partial sciatic nerve ligation; (3) osteoarthritis
pain using mechanical joint loading; (4) chemotherapy-induced pain with
oxaliplatin; (5) chronic muscle pain using hyperalgesic priming; and (6)
inflammatory pain using intraplantar complete Freund’s adjuvant. Microarray
analyses were performed using RNA isolated from dorsal root ganglia and
compared to sham/vehicle treated controls.
Differentially expressed genes (DEGs) were identified. Known andResults: 
previously unreported genes were found to be dysregulated in each pain
model. The transcriptomic profiles for each model were compared and
expression profiles of DEGs within subsets of DRG neuronal populations were
analysed to determine whether specific neuronal subsets could be linked to
each of the pain models. 
Each pain model exhibits a unique set of altered transcriptsConclusions: 
implying distinct cellular responses to different painful stimuli. No simple direct
link between genetically distinct sets of neurons and particular pain models
could be discerned.
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Introduction
Chronic pain is a major clinical problem affecting roughly 20% 
of the population with more than 6% suffering debilitating levels 
of pain1,2. Despite the huge clinical burden, little progress has 
been made in developing more effective analgesic agents. Dorsal 
root ganglion (DRG) sensory neurons are particularly exciting 
targets for drug development because of their essential role in 
driving pain sensations in the central nervous system. With the 
wider availability of high-throughput RNA-seq, there has been 
a major effort to define DRG transcriptomes, both at the level 
of whole ganglia3 and single neurons4,5. This has allowed a new 
classification of sets of sensory neurons based on genetic identity, 
rather than on the rate of action potential propagation (A fibres 
and C fibres). As well as neurons, non-neuronal cells such as glia6 
and immune system cells are found within sensory ganglia, with 
leukocytes alone making up 5–10% of cells in DRG7,8.
We wondered if the newly defined sensory neuron subsets were 
differentially activated in different pain models. We there-
fore performed microarray analyses of RNAs isolated from the 
DRG of male mice subjected to six different interventions that 
mimic common chronic pain in human patients. DRG were 
dissected after the development of peak pain behaviours in each 
case. The six different chronic pain models were: cancer cell 
injection in the intramedullary space of the femur as a model 
for bone cancer pain; partial sciatic nerve ligation (PSL) for 
neuropathic pain; mechanical joint loading for osteoarthritis 
pain; oxaliplatin-induced painful neuropathy for chemotherapy- 
induced pain; hyperalgesic priming model for chronic muscle 
pain and intraplantar complete Freund’s adjuvant (CFA) 
for inflammatory pain. The rodent models for PSL9, CFA10, 
chemotherapy induced pain with oxaliplatin11, bone cancer 
pain12 and hyperalgesic priming13–15 are well characterized. The 
mechanical joint loading model robustly recapitulates behavioural 
signs and symptoms of osteoarthritis16.
By comparing altered levels of gene expression in six 
distinct chronic pain models we hoped to gain insights into the 
neuronal subsets that are particularly important in different 
pain conditions. We also could determine genes and related path-
ways that are common or unique to each condition. Here we 
show that there is no simple relationship between transcriptional 
changes in the newly defined subsets of sensory neurons and 
particular painful insults. However, we have identified several 
known and previously unreported genes altered in expres-
sion in each pain condition. Relevant pathways and upstream 
regulators were also analysed using Ingenuity Pathway Analysis 
including cytokines, transcription factors (TFs), G-protein cou-
pled receptors (GCPRs) and ion channels. The results from 
these experiments highlight the complexity of sensory neuron cell 
types involved in nociceptive responses. Although altered DRG 
gene expression may not necessarily play a causal role in pain, 
some dysregulated genes are potential analgesic drug targets.
Methods
All experiments were performed in accordance with the UK 
Animals (Scientific Procedures) Act 1986 with prior approval 
under a Home Office project licence (PPL 70/7382). Mice were 
kept on a 12-h light/dark cycle and provided with food and water 
ad libitum. All animals were acclimatized for 1 week to the 
facility before the start of the experiment. Mice were housed in 
individually ventilated cages (Techniplast GM500 Mouse IVC 
Green line) containing Lignocel bedding with a maximum of 
5 adult mice per cage. All tests and surgeries were conducted 
using adult male C57BL/6J mice supplied by Charles River and 
Envigo (specific numbers detailed in the figure legends and 
ages detailed below for each model). Sample size for each 
behavioural model was calculated using G*Power (Ver. 3.1.9.2) 
for a power of 0.817. Surgical procedures were performed by 
trained researchers and under aseptic conditions. All efforts were 
made to ameliorate any suffering of the animals with surgery 
performed under anaesthesia. Mice were euthanized by CO2 
asphyxiation followed by cervical dislocation.
Cancer-induced bone pain
LL/2 Lewis Lung carcinoma cells (ATCC) were cultured 
in DMEM supplemented with 10% FBS and 100 units/ml 
Penicillin/Streptomycin for at least 2 weeks prior to surgery 
(cell culture reagents supplied by Thermo Fisher). Cells were 
split at 70–80% confluence four days prior to surgery. On the 
day of surgery, cells were harvested with 0.05% Trypsin-EDTA 
solution and resuspended in 1X DMEM at a final concentra-
tion of 2×107 cells/ml and kept on ice till used. Viability of 
Lewis lung carcinoma cells was confirmed at the end of surgery, 
showing 26% dead cells compared to 11% before surgery. The 
cancer cells were introduced to 12 week old mice, as previ-
ously described18,19. Sham-operated control mice underwent the 
same surgery, but were inoculated with DMEM medium alone. 
Ipsilateral L2-L4 DRGs from test and paired sham animals 
were collected when a limb score of 2 was measured in the test 
animals (see section Behavioural tests).
microCT (uCT) for bone cancer
Femurs were post-fixed in 4% PFA (Sigma-Aldrich) for 24h 
and kept in 70% ethanol (VWR) till scanning with microCT. 
Images were acquired with Skyscan software at 6.41um/pixel 
with 0.6 degrees rotation steps and 2 frame averaging. Image data 
was reconstructed with NRecon software. A CT-analyzer was 
used to select a 1mm volume of interest (VOI) region, starting at 
0.6mm from the growth plate. Bone mineral density was deter-
mined by plotting attenuation coefficients against a standard 
curve determined with two phantoms with known density. 
Representative images were binarized with ImageJ (1.52c) and 
3D Viewer extension (Java 3D 1.6 with 3D Viewer plugin 4.0.2) 
used for 3D reconstructions of femur scans.
Partial sciatic nerve ligation (PSL) model
Surgical procedures were performed under isoflurane anaes-
thesia (2–3%). A partial nerve injury in 14 week old mice was 
induced by tying a tight ligature with 6-0 silk suture around 
approximately 1/3 to 1/2 the diameter of the sciatic nerve, similar 
to the approach described in rats9. Ipsilateral and contralateral 
L3-L5 DRGs were dissected prior to RNA isolation on post- 
surgery day 16.
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Mechanical joint loading (MJL) model
In vivo loading: Osteoarthritis was induced by subjecting 12 
week old mice to a two week loading regimen using an electronic 
materials testing machine (Bose 3100). Throughout the loading 
episodes, mice were anaesthetised with isoflurane 3.5% (±0.5%) 
with the right tibia positioned vertically between two custom-
made cups which fixate the knee and ankle joint in deep flexion20. 
The loading regimen was the same as previously described16. 
Loading was repeated three times per week for two consecu-
tive weeks. The non-loaded control group consisted of age- and 
cage-matched mice that were not subjected to a loading regimen 
but received isoflurane anaesthesia for the same duration as 
loaded mice. Ipsilateral L3–L5 DRGs were dissected from 
loaded and non-loaded mice after three weeks.
Oxaliplatin pain model
Seven week old mice were injected with either oxaliplatin 
(6mg/kg/i.p., Sigma-Aldrich) or vehicle solution (5% glucose, 
Sigma-Aldrich) as a control twice weekly for four weeks11,21. 
Ipsilateral L3–L5 DRGs were dissected prior to RNA isolation 
from oxaliplatin and vehicle treated mice on day 28.
Chronic muscle pain model
Eight week old mice were injected twice, four days apart, with 
30ul of 3% carrageenan (Sigma-Aldrich) (primed group; n=4) 
or saline (VWR) (control group; n=4) into the ipsilateral right 
gastrocnemius muscle13. Ipsilateral L3–L5 DRGs were dissected 
prior to RNA isolation on day 29.
Complete Freund’s adjuvant (CFA) pain model
Eleven week old mice received intraplantar injection of 
20 ul of Complete Freund’s adjuvant (CFA, Sigma-Aldrich) 
or 0.9% sodium chloride solution (VWR) into the left hind 
paw22,23. Ipsilateral L3-L5 DRGs were then dissected prior to 
RNA isolation from CFA and saline treated mice 2 days after 
treatment.
Behavioural tests
For behavioural experiments, animals were acclimatized to the 
equipment for at least 2 days prior to testing. Observers who 
performed behavioural experiments were blind to the test/sham 
groups. The cancer induced bone pain model used a limb 
score assessment, as previously described19. A limb score of 2 
(i.e. significant limping) was used as the checkpoint for ending 
the experiment with DRGs and ipsilateral femurs collected.
Mechanical sensitivity was measured using the up-down 
method24 and static weight bearing18 assays. Thermal nocic-
eptive thresholds were determined by measuring paw withdrawal 
latency using the Hargreaves’ apparatus25. The response to 
noxious cold was measured using the cold plantar assay26.
RNA extraction and microarrays
RNA was extracted using TRIzol Reagent (Life Technologies) 
and Purelink RNA micro kit (Thermo Fisher) according to the 
manufacturer’s instructions. RNA samples from four animals 
displaying the most marked pain behaviours for each model 
were sent for microarray analyses together with four controls 
(Eurofins AROS) using the Affymetrix GeneChip Mouse 
Transcriptome Array 1.0 and WT pico kit. Four replicates give a 
statistical power of >0.8 to detect a 2 fold change27,28. Microarray 
data has been deposited at Gene Expression Omnibus Array 
Express for public use with reference number E-MTAB-6864.
Differential gene expression (DGE) and splice variant 
analysis
Differential gene expression (DGE) and splice variant analysis 
of transcriptome array data was performed using Transcriptome 
Analysis Console (TAC Ver 4.0, Thermo Fisher). Normalization 
was carried out according to the manufacturer’s default protocol 
converting probe cell intensity (CEL files) into signal data (CHP 
files). An ANOVA (eBayes) cut-off p-value of <0.05 was used 
to identify DEGs, with the fold change filter then used to sort 
genes. Genes without a curated gene symbol associated with the 
Affymetrix probe set were excluded from downstream DGE 
analyses. Differentially expressed genes (DEGs) were corre-
lated with known expression in DRG neuronal subtypes4. Splice 
variant analysis was performed using the Gene + Exon func-
tion in TAC which uses a gene normalized intensity value (ratio 
of probe set intensity to gene expression level). The cut off was 
set at Splicing Index of 2, splicing ANOVA with p<0.05, gene 
expressed in both conditions, probe selection region (PSR)/
junction expressed in at least one condition and gene contain-
ing at least one PSR. Non-coding genes were excluded from 
the splicing analyses. An exon event score indicated consensus 
alternative splicing event score where a score of 1 represents a 
high likelihood of splicing event. Heatmaps, volcano plots and 
statistical analyses were generated using GraphPad Prism 7.
Ingenuity Pathway Analysis (IPA)
Ingenuity Pathway Analysis (IPA, Qiagen) for upstream regu-
lators was performed according to the manufacturer’s instruc-
tions. IPA primarily utilizes published results of knockdown 
or knockout studies of genes characterized as growth factor, 
kinase/phosphatase, transcription/translation regulator, cytokine, 
transmembrane receptor, enzyme, ion channel, transporter, 
G-protein coupled receptor, peptidase, and microRNA. This 
analysis examines target genes from the array dataset, compares 
their direction of change to what is expected from the literature 
to predict likely upstream regulators using overlap p-value 
(Fishers Exact Test, p<0.01) and an activation z-score corrected 
for bias. The top upstream regulators with an activation z-score 
were examined for each pain pathway. The activation z-score was 
used to make a prediction regarding activation or inhibition of 
the upstream regulator.
Results
We modelled six different chronic pain conditions in mice and 
used behavioural assays to confirm the development of mechani-
cal or thermal hypersensitivity, followed by transcriptomic 
analyses of whole dorsal root ganglia tissue. Significant DGE 
between naïve and injured conditions and alternative splicing was 
assessed for each model. DGE values for every gene on the mouse 
transcriptome array and alternative splicing changes are available in 
Supplementary Table 1.
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Cancer-induced bone pain
Carcinoma cells were introduced into the mouse femur and 
pain behaviour measured daily to determine the limb use score 
(4: normal use of limb, 3: slight limping, 2: clear limping; see 
Methods). Mice were culled when a limb score of 2 was 
reached, which ranged from Day 8–16 post surgery (Figure 1A). 
Weight bearing tests confirmed a significant reduction in use 
of the affected limb (Figure 1B). Bone mineral density (BMD) 
was evaluated as an additional indicator of the cancer phenotype 
and was shown to be significantly decreased in cancer mice 
compared to sham controls (Figure 1C, D). This is also shown 
in Figure 1E using a micro-CT reconstruction.
Dorsal root ganglia (ipsilateral L2–L4) were isolated from test 
mice and paired sham controls and RNA expression levels ana-
lysed using microarrays. The volcano plot (Figure 1F) shows that 
all significantly dysregulated genes (p<0.05) were differentially 
expressed between ±10-fold with only 1 non-coding gene 
(Gm25931) falling outside of this range (fold change of -10.75). 
Interestingly, very few of the differentially expressed DRG 
genes in the cancer induced bone pain model were shared with 
other models (Figure 1G). A heat map was generated for genes 
that were significantly up or down regulated by 2 fold or more 
(Figure 1H). Forty-five genes were found to be upregulated >2 
fold and 15 genes downregulated. Dysregulated genes were 
coding and non-coding, with many genes annotated as ‘predicted’ 
(Supplementary Table 1). Excluding these ‘predicted’ genes, 
the top 5 most upregulated genes were Nts, miR6898, Snord49b, 
Sprr1a and Gal (Figure 1H). The cancer induced bone pain 
model induced significant changes in 23 microRNAs in the 
>1.5 fold range, indicating the potential role of miRNAs in cancer 
pain modulation (Supplementary Figure 2A).
Partial sciatic nerve ligation (PSL) model
In the PSL neuropathic pain model mice developed mechanical 
allodynia from Day 7 post surgery, as characterized by a signifi-
cant reduction in the 50% paw withdrawal threshold (PWT) in the 
injured (ipsilateral) compared to the non-injured (contralateral) 
paw (Figure 2A). Pain persisted for 15 days post-surgery, with 
ipsilateral and contralateral L3-L5 DRGs isolated on day 16 and 
RNA analysed by microarrays.
The volcano plot (Figure 2B) shows that all significantly 
dysregulated genes (p<0.05) were differentially expressed 
between ±10-fold with the exception of Nts, Gpr151 and Npy 
(respective fold changes of 13.21, 13.88 and 66.18). Similar to 
the cancer model, very few PSL stimulated genes were shared 
with other pain models (Figure 2C). The PSL model stimulated 
changes in the largest cohort of DRG genes in the 2 fold change 
range (97 genes) compared to the other 5 models (Figure 2D). 
The top 5 most upregulated genes, Npy, Gpr151, Nts, Gal and 
Atf3, have all been previously reported as being upregulated in 
neuropathic pain29–32. Eighty-six genes were identified as being 
upregulated more than 2 fold with several of these being non- 
coding RNAs (Supplementary Table 1). Fourteen microRNAs 
were upregulated >1.5-fold and 5 were downregulated <-1.5- fold 
(p<0.05, ANOVA) (Supplementary Figure 2B).
Mechanical joint loading (MJL) model
Osteoarthritis was induced through a two-week mechanical 
joint loading protocol after which animals developed signifi-
cant mechanical hypersensitivity and altered weight bearing 
(Figure 3A). Ipsilateral L3–L5 DRGs from loaded and non-
loaded mice were extracted 3 weeks after the loading regi-
men, RNA extracted and analysed for DEGs. The volcano plot 
(Figure 3B) shows that all significantly dysregulated genes 
(p<0.05) were differentially expressed between ±7-fold. Only 
fourteen genes were dysregulated >2 fold (Figure 3D) with 
only 1–2 of these genes also differentially expressed in the 
other pain models (Figure 3C). The top three upregulated genes 
(Ppbp, DLEU2_5 and Scarna9) have no previous association 
with osteoarthritic pain.
Oxaliplatin-induced painful neuropathy
Oxaliplatin is a chemotherapeutic drug known to induce mechani-
cal and cold allodynia33. Mice exposed to oxaliplatin were 
found to have a reduced cold pain threshold in the cold plantar 
test (Figure 4A). Twenty-eight days following the first oxali-
platin treatment, ipsilateral L3–L5 DRGs were extracted from 
test and vehicle treated mice and analysed for differential gene 
expression. The volcano plot (Figure 4B) shows that all sig-
nificantly dysregulated genes (p<0.05) were differentially 
expressed between ±10-fold. Oxaliplatin treatment resulted in 
58 dysregulated genes in the >2 fold range, which in contrast to 
other models, the majority (36 genes) being down- rather than 
up-regulated (Figure 4D). Out of the 58 DEGs, 7 were shared with 
the CFA model, 3 with the PSL model and 2 with the mechanical 
joint loading model (Figure 4C).
Chronic muscle pain (CMP)
A hyperalgesic priming model was used to study chronic 
muscle pain, whereby the gastrocnemius muscle was injected 
twice, four days apart, with 3% carrageenan. Prolonged mechani-
cal hypersensitivity resulted from the hyperalgesic priming 
(Figure 5A). On Day 29, ipsilateral L3-L5 DRGs were extracted 
from test and vehicle treated mice and analysed for DGE. 
The volcano plot (Figure 5B) shows that all significantly 
dysregulated genes (p<0.05) were differentially expressed between 
±5-fold. Interestingly, only ten genes were dysregulated >2 
fold (Figure 5D) with Snord49b shared with the cancer-induced 
bone pain model and Gm19860 shared with the mechanical joint 
loading model (Figure 5C).
CFA inflammatory pain model
Intraplantar injection of CFA was used to induce a robust 
inflammatory pain phenotype, with significant thermal hyper-
sensitivity observed thirty-six hours post CFA injection 
(Figure 6A). Ipsilateral L3–L5 DRGs were extracted 2 days 
post CFA and RNA analysed for differential gene expression. 
The volcano plot (Figure 6B) shows that all significantly dys-
regulated genes (p<0.05) were differentially expressed between 
±9-fold. Seventy genes were differentially expressed >2 fold with 
the majority of genes (52) being upregulated (Figure 6D). Once 
again, very few dysregulated genes were shared between CFA 
and the other models (Figure 6C).
Page 5 of 19
Wellcome Open Research 2018, 3:78 Last updated: 18 JUL 2018
Figure 1. Differential gene expression in the cancer induced bone pain model. (A) Survival curve after surgery for sham (black line, n=7) 
and cancer (grey line, n=7) animals with endpoint defined as clear limping on the affected limb (limb score=2). Log-rank test: p=0.0056. 
(B) Percentage weight bearing on the affected limb is significantly reduced at the endpoint (limb score=2) for cancer compared to sham 
animals (2-way ANOVA with posthoc Bonferonni test: p<0.0001.) (C) Trabecular bone mineral density (unpaired t-test: p=0.0003) and 
(D) cortical bone mineral density (unpaired t-test: p=0.0033) in cancer vs. sham animals. (E) Representative 3D reconstructions of a 1mm 
VOI at 0.6mm from growth plate from uCT data (7 replicates per group). (F) Volcano plot for all genes identified in the bone cancer pain array. 
Each dot represents a single gene (red=upregulated; blue=downregulated). (G) Venn diagram showing the number of differentially 
expressed DRG genes (fold change >2, <-2, p<0.05) shared with other pain models. (H) Heat map of upregulated (red) and downregulated 
(blue) DRG genes (fold change >2, <-2, p<0.05) and a comparison of shared genes across models. Genes with an asterisk are present within 
the Pain Genes Database of pain-related transgenic knockout studies34.
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Figure 2. Differential gene expression in the partial sciatic nerve ligation (PSL) neuropathic pain model. (A) Mechanical sensitivity using 
von Frey filaments on ipsilateral and contralateral paws following PSL surgery (n=4, **indicates p<0.01, ****indicates p<0.0001, 2-way ANOVA 
with posthoc Bonferonni test). PWT = paw withdrawal threshold. (B) Volcano plot for all genes identified in the PSL pain model array. Each dot 
represents a single gene (red=upregulated; blue=downregulated). (C) Venn diagram showing the number of differentially expressed DRG 
genes (fold change >2, <-2, p<0.05) shared with other pain models. (D) Heat map of upregulated (red) and downregulated (blue) DRG genes 
(fold change >2, <-2, p<0.05) and a comparison of shared genes across models. Genes with an asterisk are present within the Pain Genes 
Database of pain-related transgenic knockout studies34.
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Figure 3. Differential gene expression in the mechanical joint loading (MJL) model. (A) Development of mechanical hypersensitivity and 
altered weight bearing after osteoarthritis (OA) induction by mechanical joint loading. Mice were loaded three times per week for two weeks 
at 9N (grey line, error bars given as SEM, n=6) in order to induce OA. Behavioural measurements were taken before OA induction and each 
week for three weeks post loading. These values were compared to a non-loaded isoflurane control (black hashed line, error bars given as 
SEM, n=6). Significant changes between non-loaded animals and loaded animals are indicated with a # (p<0.05, 2-way ANOVA with posthoc 
Dunnett or Sidak tests) whilst significant changes within experimental groups over time (compared to baseline value) are indicated with a * 
(p<0.05, 2-way ANOVA with posthoc Dunnett or Sidak tests). (B) Volcano plot for all genes identified in the MJL array. Each dot represents 
a single gene (red=upregulated; blue=downregulated). (C) Venn diagram showing the number of differentially expressed DRG genes (fold 
change >2, <-2, p<0.05) shared with other pain models. (D) Heat map of upregulated (red) and downregulated (blue) DRG genes (fold 
change >2, <-2, p<0.05) and a comparison of shared genes across models.
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Figure 4. Differential gene expression in the oxaliplatin pain model. (A) Cold hypersensitivity induced by oxaliplatin (6 mg/kg, i.p.) at Day 
27 (5% glucose solution was used as control). Significant changes are indicated with * (n=6 per group, *p<0.05, paired t-test). (B) Volcano 
plot for all genes identified in the oxaliplatin model array. Each dot represents a single gene (red=upregulated; blue=downregulated). (C) 
Venn diagram showing the number of differentially expressed DRG genes (fold change >2, <-2, p<0.05) shared with other pain models. (D) 
Heat map of upregulated (red) and downregulated (blue) DRG genes (fold change >2, <-2, p<0.05) and a comparison of shared genes 
across models. Genes with an asterisk are present within the Pain Genes Database of pain-related transgenic knockout studies34.
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Figure 5. Differential gene expression in the chronic muscle pain model. (A) Widespread mechanical hypersensitivity in a mouse model 
of the transition from acute to chronic musculoskeletal pain. Mice were injected twice with 3% carrageenan i.m. (primed group) or saline 
(control group) into the gastrocnemius muscle (n=4 per group). Injections are indicated by arrows and mechanical withdrawal thresholds 
were assessed in the glabrous skin of the ipsilateral hind paw. Significant changes denoted by *** (***p<0.001 Primed vs Control, 2-way 
ANOVA with repeated measures and Bonferroni post hoc tests). (B) Volcano plot for all genes identified in the chronic muscle pain model 
array. Each dot represents a single gene (red=upregulated; blue=downregulated). (C) Venn diagram showing the number of differentially 
expressed DRG genes (fold change >2, <-2, p<0.05) shared with other pain models. (D) Heat map of upregulated (red) and downregulated 
(blue) DRG genes (fold change >2, <-2, p<0.05) and a comparison of shared genes across models.
Expression of pain-related DEGs in DRG neuronal subsets
Single cell RNA sequencing of mouse DRG neurons has iden-
tified 11 distinct subsets of neurons4. To determine whether 
particular DRG neuronal populations are enriched with DEGs, 
we created heat maps for each model that show expression of 
every neuronal DEG (fold change >±1.5 fold; p<0.05) and com-
pared this with the basal expression of each gene in the Usoskin 
et al. dataset4 (Figure 7A–F, Supplementary Figure 1A–F). Next, 
the percentage of DEGs was correlated with each subpopulation 
of DRG neurons (Figure 7G). This indicated that there were no 
clear trends for the expression pattern of the DEGs for each 
model, with the exception of oxaliplatin where DEGs clustered 
in the NF1-5 and PEP2 subgroups (myelinated neurofilament- 
heavy (Nefh) positive neurons).
Analysis of upstream regulators of neuronal DEGs in 
chronic pain models
Next, we analysed pathways and upstream regulators implicated 
in the four pain conditions with the highest number of DEGs 
using the Ingenuity Pathway Analysis program. The top 
upstream regulators in the bone cancer pain model are shown in 
Figure 8A (p-value of overlap <0.05, ANOVA) and includes 
cytokine IFNG (activation z-score 1.9); growth factor LEP 
(activation z-score 0.4); and transcription regulator NFE2L2 
(activation z-score 1.9). The analysis was unable to determine 
whether these regulators were activated or inhibited. The top 
upstream regulators in the PSL model are depicted in Figure 8B 
(p-value of overlap<0.05, ANOVA), and includes growth factors 
TGFB1 (activation z-score 2.2, predicted to be activated) and 
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Figure 6. Differential gene expression in the complete Freund’s adjuvant (CFA) inflammatory pain model. (A) Heat hypersensitivity 
post CFA intraplantar injection (20 microliters) in mice. Significant changes are indicated with ** (n=6 per group, ** p<0.01, 2-way ANOVA). 
(B) Volcano plot for all genes identified in the CFA pain model array. Each dot represents a single gene (red=upregulated; blue=downregulated). 
(C) Venn diagram showing the number of differentially expressed DRG genes (fold change >2, <-2, p<0.05) shared with other pain models. (D) 
Heat map of upregulated (red) and downregulated (blue) DRG genes (fold change >2, <-2, p<0.05) and a comparison of shared genes across 
models. Genes with an asterisk are present within the Pain Genes Database of pain-related transgenic knockout studies34.
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Figure 7. Pattern of dorsal root ganglion (DRG) neuron expression of differentially expressed genes (DEGs) identified in the six pain 
models. Expression pattern in (A) Bone cancer, (B) partial sciatic nerve ligation (PSL), (C) mechanical joint loading (MJL), (D) Oxaliplatin, 
(E) chronic muscle pain (CMP) and (F) complete Freund’s adjuvant (CFA) models of the DEGs and their basal expression pattern in the 11 
different subtypes of DRG neurons (NF1-5, NP1-3, PEP1-2, TH) based on the classification described by Usoskin et al.4. NF1, NF2 and NF3 
correspond to low-threshold mechanoreceptors (LTMRs); NF4 and NF5 correspond to proprioceptors; NP1, NP2 and NP3 are unmyelinated, 
nonpeptidergic neurons; PEP1 are unmyelinated, peptidergic neurons; PEP2 are myelinated, peptidergic neurons; and TH neurons are type C 
low-threshold mechanoreceptors (C-LTMRs) that are unmyelinated. Analysis has been restricted to DEGs with a fold-change greater than 1.5 
or less than -1.5 (p<0.05) with at least 20% expression in 1 or more of the neuronal subgroups in the Usoskin et al. dataset4. (G) Transcriptional 
preference for distinct DRG neuronal subpopulations (described previously) in each pain model. This graphical estimation is based on a 
particular gene being expressed in 50% or more of a particular neuronal subpopulation and presented as a percentage of the total DEGs 
shared with the Usoskin et al. dataset4 at >1.5 or <-1.5 fold (p<0.05).
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Figure 8. Top upstream regulators of differentially expressed genes identified in bone cancer, partial sciatic nerve ligation 
(PSL), oxaliplatin, and complete Freund’s adjuvant (CFA) models. Upstream regulators were identified for (A) Bone cancer, (B) PSL, 
(C) Oxaliplatin and (D) CFA. Bias corrected activation z-score predicts likelihood of activation (+ive score) or inhibition (-ive score) of the 
molecular pathway.
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BMP7 (activation z-score -1.9); cytokines TNF, IL-6, IL-1-beta 
(activation z-scores > 2, all predicted to be activated in PSL); 
kinase MTOR (activation z-score 2.3, predicted to be activated); 
and the transcription regulator GATA4 (activation z-score -
2.8). In the oxaliplatin model (Figure 8C) the top upstream 
regulators (p<0.05, ANOVA) involved included cytokines 
IFNG, IFNL1, PRL (activation z scores< -2, all predicted to be 
inhibited) and IL1RN (activation z score >2, predicted to be 
activated); G-protein coupled receptor ACKR2 (activation z 
score 3, predicted to be activated); and transcription regulators 
TRIM24, SIRT1, STAT3 (activation z scores > 2, all predicted to 
be activated) and STAT1 (activation z score <-3, predicted to 
be inhibited). Finally, for CFA the top upstream regulators 
(p<0.05, ANOVA) included cytokines IFNG, IL-1B and IFN-B1 
(activation z scores>1.7, all predicted to be activated); transcrip-
tion regulator STAT1 (activation z score 1.8, predicted to be 
activated) and TRIM24 (activation z score -1.47, predicted to 
be inhibited) (Figure 8D). We observed interesting patterns of 
activation compared to inhibition of upstream regulators between 
pain models. For example, STAT1 is activated in oxaliplatin, 
but inhibited in the CFA model; IFNG is activated in CFA and 
PSL, but inhibited in the oxaliplatin model.
Discussion
DRG sensory neurons are a heterogeneous population that 
have recently been classified according to their gene expression 
profiles4. By modelling six chronic pain conditions in mice we 
aimed to (1) identify dysregulated DRG genes in each model; 
(2) map dysregulated genes to one or more of the 11 neuronal 
subsets; and (3) determine whether different pain models shared 
similar dysregulated genes and/or neuronal subsets. Overall our 
analysis highlighted how dissimilar the different models were 
in respect to their transcriptomic profiles with the majority of 
dysregulated genes not shared between models (see Venn 
diagrams in Figure 1–Figure 6). This implies that chronic pain can 
arise from a diverse set of mechanisms involving different genes 
and pathways. Although transcriptional changes may not be causa-
tive in the pain induction, the present study suggests distinct cell 
and molecular mechanisms are involved with associated tran-
scriptional correlates in the pain models studied. Although some 
key genes were shared between models, such as Neurotensin and 
Galanin being upregulated in cancer induced bone pain and PSL 
neuropathic pain models, the majority of dysregulated genes were 
exclusive to each pain model.
We also largely failed to link narrow subsets of DRG neurons 
to particular chronic pain models using microarray analyses 
(see Figure 7). Our aim was to identify dysregulated genes 
from the microarrays and map these genes to the neuronal 
populations previously outlined using single cell RNAseq 
data4. However, this approach was limited by the fact that the 
published RNAseq data is derived from naïve mice (i.e. not in 
pain) and potentially the gene expression patterns across the 
neuronal subsets may dynamically change in the pain models. 
This is certainly true for genes such as Galanin which is 
markedly upregulated and expressed in ~40–50% of DRG neu-
rons following axotomy32 and BDNF, which is upregulated in 
medium and large diameter DRG neurons in neuropathic pain35. 
Furthermore, genes that have no DRG expression in the Usoskin 
et al. dataset (i.e. zero sequencing reads) were not included in 
our transcriptomic analyses, but could be expressed following 
injury. For example, Neuropeptide Y is dramatically upregulated 
in DRG neurons following peripheral nerve injury, but is not 
expressed in basal conditions29. Thirdly, many genes are broadly 
expressed in several DRG populations, meaning that restricted 
critical subsets are difficult to highlight.
Recent advances in deep sequencing have dramatically 
increased the number of known transcribed genes36. The Mouse 
Transcriptome Array that we used gives a comprehensive 
coverage of the mouse transcriptome, with >214,000 transcripts 
represented. Genes that are represented include both coding and 
non-coding genes (such an lncRNAs, small RNAs and expressed 
pseudogenes). Although such genes are now known to be 
expressed, gene annotation and understanding of gene func-
tion is lagging behind. This is highlighted in our transcriptomic 
analyses where a high number of predicted genes (typically 
with the ‘Gm’ prefix) showed differential expression. A major 
challenge is to determine the function of these types of genes 
and to ascertain the contribution, if any, to the pain phenotypes 
observed. Similarly, although the dense probe coverage on the 
array gives the opportunity to assess differential splicing patterns 
(Supplementary Figure 3), experimental verification is needed to 
prove that the changes in splicing patterns are relevant.
Given the unique sets of underlying genes, we attempted to 
identify potential common upstream regulators using IPA 
analyses. We identified several common cytokines as upstream 
regulators of DEGs in our pain models consistent with the role 
of cytokines in generation and maintenance of pain37,38, point-
ing to the interaction of DRG neurons and immune cells as a key 
point of focus. T cells are known to infiltrate DRGs in models 
of neuropathic pain39–41, however whether the cytokine related 
downstream DEGs identified in our pain models are being 
induced by immune cells remains to be investigated.
In summary, we present a systematic study of the transcrip-
tomic changes in six different chronic mouse pain models as a 
resource for the pain community. Although gene expression 
changes may not be causally linked to the pain phenotypes 
observed, the transcriptomic profiles reported here highlight the 
diversity of cell and molecular mechanisms apparent in 
different pain conditions. Potential therapeutic gene targets for 
the distinct chronic pain conditions studied may also be identified 
after further mechanistic studies.
Data availability
Microarray data has been deposited at Gene Expression Omnibus 
Array Express for public use with reference number E-MTAB-
6864.
DGE data (Supplementary Table 1), replicates for Figure 1E (3D 
reconstruction images) and raw values in a GraphPad Prism file 
for Figure 1A-D, Figure 2A, Figure 3A, Figure 4A, Figure 5A 
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and Figure 6A for all replicates are deposited in OSF: https://doi.
org/10.17605/OSF.IO/DG7Z342 
Data are available under the terms of the Creative Commons Zero 
“No rights reserved” data waiver (CC0 1.0 Public domain dedica-
tion).
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Supplementary material
Supplementary Table 1: Differential gene expression values for all genes on the mouse transcriptome array and alternative splicing 
changes. Differential gene expression and splice variant analysis of transcriptome array data was performed using Transcriptome Analysis 
Console (TAC Ver 4.0, Thermo Fisher). Normalization was carried out according to the manufacturer’s default protocol converting probe 
cell intensity (CEL files) into signal data (CHP files).
Splice variant analysis was performed using the Gene + Exon function in TAC which uses a gene normalized intensity value (ratio of 
probe set intensity to gene expression level).
Click here to access the data.
Supplementary File 1: Supplementary figures. 
Click here to access the data.
Supplementary Figure 1: Differentially expressed DRG neuron genes. Differentially expressed genes in (A) Bone cancer, (B) PSL, 
(C) MJL, (D) Oxaliplatin, (E) CMP and (F) CFA with known basal DRG neuron expression in the Usoskin et al. dataset4. Genes listed 
here correlate with those shown in Figure 7. Analysis has been restricted to DEGs with a fold-change greater than 1.5 or less than -1.5 
(p<0.05) with at least 20% expression in 1 or more of the neuronal subgroups in the Usoskin et al. dataset4. Genes with an asterisk are present 
within the Pain Genes Database of pain-related transgenic knockout studies34.
Supplementary Figure 2: Differentially expressed microRNA genes. Differentially expressed microRNA DRG genes in (A) Bone 
cancer, (B) PSL, (C) MJL, (D) Oxaliplatin, (E) CMP and (F) CFA pain models (fold change >1.5, <-1.5).
Supplementary Figure 3: Differential splicing analyses. Top 10 splice variants for (A) Bone Cancer, (B) PSL, (C) MJL, (D) Oxaliplatin, 
(E) Chronic Muscle Pain and (F) CFA. Attached heat map for each model shows the splicing index (SI) of the spliced genes (exon SI >2 
or <-2, Exon p-val <0.05). Exon event score calculated by TAC software (see methods) where 1 represents a high likelihood for the spliced 
event. Exon events were defined in TAC as: Intron retention- when a sequence is spliced out as an intron or remains in the mature mRNA 
transcript; Cassette Exon (skipped exon) – when one exon is spliced out of the primary transcript together with its flanking introns; Alterna-
tive 3`acceptor site when two or more splice sites are recognized at the 5` end of an exon, an alternative 3` splice junction is used changing 
the 5` boundary of the downstream exon; Alternative 5` donor site when two or more splice sites are recognized at the 3` end of an exon, an 
alternative 5` splice junction is used changing the 3` boundary of the upstream exon.
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The paper discovers differentially expressed genes in mouse primary sensory neurons (DRG) in a variety
of pain models that are believed to be models of  human pain states. Looking in the primary neurons the
authors find that, although pain levels appear similar and significant in all the models studied, the changes
in gene expression for each of the pain states is different. The paper is of great interest, and I have
enjoyed trying to grapple with its contents. This is a way of saying that I like it, but I wanted to clarify a
couple of things, that have raised a flag.
The discussion is written as though no gene expression data have ever been obtained before in pain
models, and I agree with David Wynick that a more helpful approach would require that some context is
offered in the discussion, particularly as this group of authors are generating a benchmark. For example,
with reference to the findings on local inflammation, in Figure 2D I do not see a single sodium channel
gene affected, and yet Na+ channel genes are reported by others to be dysregulated, for example NaV1.3
expression is reported to double in DRG in inflammatory circumstances . Do the authors think this is
surprising and what is the reader to make of this? In fact, is Na+ channel gene expression in DRG
neurons affected at all by any of the induced pain states? What has happened to other potentially
important pain related ion channels such as KCNQ and HCN channels?
Is one correct deduction then that while there may indeed be stereotyped gene expression changes
taking place (given that somehow the maladaptive changes in the nervous system exist for all these pain
scenarios) they must be in second and higher order neurons, involving glutamate gated ion channel
subunits and so on?
Secondly, as it seems inescapable to conclude that the membrane behaviour of primary sensory neurons
must be somehow ‘abnormal’ in pain states driven from the periphery, is the correct conclusion that this is
precipitated without any necessity of modification of ion channel expression, completely by a combination
of already latent functionality and post-translational modification.
I would like a little more clarification on Figure 7. I think the authors are looking a for a pattern of gene
dysregulation that might conspicuously ‘fit’ the already discovered baseline gene expression profiles of
sub-populations of neurons. I think I understand that fitting the profiles against each subtype (previously
described) reveals nothing useful, but I would be happy with a bit more explanation for this (bottom page
10 and Figure 7), as I want to rid myself of (I think !) the erroneous impression that single cell analysis is
going on.
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This is a well written paper that is clearly and accurately presented. The study design is appropriate and
the work is technically sound. The data substantially expands the current evidence-base in this field.
The authors have used transcriptional profiling to identify differentially expressed genes in the mouse
DRG following six different chronic pain models. Most interestingly and unexpectedly, they found almost
no similarity between the transcriptional changes in expression with very little overlap in the genetic
signatures between the models.
Points that could be further expanded upon in the discussion:
Place the current dataset in the context of the previous published studies that have used
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 Place the current dataset in the context of the previous published studies that have used
transcriptional profiling on the DRG after different pain models (and in some cases comparing two
different models), and whether the previous findings and genes identified are consistent with the
current data.
Identifying genes in the DRG on the basis of their fold-change after a pain model does not mean
that those genes are necessarily involved in mediating pain. Indeed, many of the targets of the
current analgesics used in clinical practice do not show >two-fold change in expression in mouse
models. It is quite possible that many of the genes that do show large changes in each model play
roles that relate to apoptosis, survival and/or regeneration, rather than pain transmission and
nociception.
The main finding of this paper provides further evidence that it may not be possible to identify
targets in the final common nociceptive pathway that will target all causes of pain and would be
amendable to drug discovery. A more targeted and mechanistic approach is likely to be necessary
to focus more on specific pathways that are activated and thus on the individual diseases that
cause the pain.
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